Table 3.

Univariate and multivariate Cox proportional-hazard regression analyses for PFS and OS in 319 patients with WM treated with ibrutinib monotherapy

PFS	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	P	HR (95% CI)	P
Age >65 years	1.21 (0.77-1.89)	.41
Male sex	1.09 (0.67-1.78)	.72
Hemoglobin <11.5 g/dl	1.40 (0.84-2.32)	.19
Platelet <100 k/ul	2.55 (1.42-4.59)	.002	2.51 (1.28-4.89)	.007
β2-microglobulin >3 mg/l	1.48 (0.84-2.61)	.17
Albumin <3.5 g/dl	1.57 (0.97-2.57)	.07
Serum IgM >4000 mg/dl	0.90 (0.58-1.41)	.64
Serum IgM >7000 mg/dl	1.90 (0.76-4.73)	.17
Bone marrow >60%	0.75 (0.47-1.22)	.25
Previously treated	1.40 (0.77-2.53)	.27
CXR4 mutated	2.31 (1.41-3.79)	.001	1.98 (1.17-3.36)	.01
CXCR4 WT	1.00
CXCR4 NS	2.93 (1.71-5.00)	<.001	2.56 (1.54-4.50)	.001
CXCR4 FS	1.49 (0.68-3.23)	.32	1.22 (0.55-2.74)	.63
OS	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	P	HR (95% CI)	P
Age >65 years	3.03 (1.61-5.70)	.001	3.15 (1.41-7.04)	.005
Male sex	1.55 (0.81-2.95)	.18
Hemoglobin <11.5 g/dl	2.36 (1.15-4.84)	.02	2.00 (0.81-4.93)	.13
Platelet <100 k/ul	3.10 (1.61-5.97)	.001	2.05 (0.94-4.48)	.07
β2-microglobulin >3 mg/l	3.01 (1.27-7.18)	.01	1.69 (0.69-4.14)	.25
Albumin <3.5 g/dl	2.40 (1.37-4.24)	.002	1.65 (0.85-3.19)	.14
Serum IgM >4000 mg/dl	1.39 (0.81-2.39)	.23
Serum IgM >7000 mg/dl	2.07 (0.74-5.77)	.17
Bone marrow >60%	0.87 (0.49-1.54)	.63
Previously treated	1.46 (0.67-3.15)	.34
CXCR4 mutated	1.37 (0.74-2.53)	.31
CXCR4 WT	1.00
CXCR4 NS	1.42 (0.71-2.85)	.32
CXCR4 FS	1.49 (0.61-3.64)	.39

MYD88 mutational status was not included as the sample size for MYD88 wild-type status was small (n = 8).

See Table 2 for definitions.